



FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/817,165	ATTY. DOCKET NO.: C1039.70048US02
				FILING DATE: April 2, 2004	CONFIRMATION NO.: 1597
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield
Sheet	1	of	16		

#### U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1	5,112,605		Jardieu et al.	05-12-1992
	A2	5,498,410		Gleich	03-12-1996
	A3	5,663,153		Hutcherson et al.	09-02-1997
	A4	5,679,647		Carson et al.	10-21-1997
	A5	5,681,555		Gleich	10-28-1997
	A6	5,723,335		Hutcherson et al.	03-03-1998
	A7	5,726,160		McMichael	03-10-1998
	A8	5,804,566		Carson et al.	09-08-1998
	A9	5,849,719		Carson et al.	12-15-1998
	A10	5,908,620		Tu et al.	06-01-1999
	A11	5,955,059		Gilchrest et al.	09-21-1999
	A12	5,955,442		McMichael	09-21-1999
	A13	5,994,315		Nyce et al.	11-30-1999
	A14	6,025,339		Nyce et al.	02-15-2000
	A15	6,040,296		Nyce et al.	03-21-2000
	A16	6,096,721		McMichael	08-01-2000
	A17	6,100,244		McMichael	08-08-2000
	A18	6,174,872	B1	Carson et al.	01-16-2001
	A19	6,194,388	B1	Krieg et al.	02-27-2001
	A20	6,207,646	B1	Krieg et al.	03-27-2001
	A21	6,214,806	B1	Krieg et al.	04-10-2001
	A22	6,218,371	B1	Krieg et al.	04-17-2001
	A23	6,221,882	B1	Macfarlane	04-24-2001
	A24	6,225,292	B1	Raz et al.	05-01-2001
	A25	6,239,116	B1	Krieg et al.	05-29-2001
	A26	6,339,068	B1	Krieg et al.	01-15-2002
	A27	6,399,630	B1	Macfarlane	06-04-2002
	A28	6,406,705	B1	Davis et al.	06-18-2002
	A29	6,426,336	B1	Carson et al.	07-30-2002
	A30	6,429,199	B1	Krieg et al.	08-06-2002
	A31	6,479,504	B1	Macfarlane et al.	11-12-2002
	A32	6,498,148	B1	Raz	12-24-2002

EXAMINER:

/N. M. Minnifield/ (06/03/2008)

DATE CONSIDERED:

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

APPLICATION NO.: 10/817,165

ATTY. DOCKET NO.: C1039.70048US02

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

FILING DATE: April 2, 2004

CONFIRMATION NO.: 1597

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

Sheet

2

of

16

A33	6,514,948	B1	Raz et al.	02-04-2003
A34	6,521,637	B2	Macfarlane	02-18-2003
A35	6,562,798	B1	Schwartz	05-13-2003
A36	6,589,940	B1	Raz et al.	07-08-2003
A37	6,610,661	B1	Carson et al.	08-26-2003
A38	6,653,292	B1	Krieg et al.	11-25-2003
A39	6,727,230	B1	Hutcherson et al.	04-27-2004
A40	6,787,524	B2	Chang et al.	09-07-2004
A41	6,821,957	B1	Krieg et al.	11-23-2004
A42	6,943,240	B2	Bauer et al.	09-13-2005
A43	6,949,520	B1	Hartmann et al.	09-27-2005
A44	6,951,845	B2	Carson et al.	10-04-2005
A45	7,001,890	B1	Wagner et al.	02-21-2006
A46	7,223,741	B2	Krieg	05-29-2007
A47	2001-0044416	A1	McCluskie et al.	11-22-2001
A48	2002-0064515	A1	Krieg et al.	05-30-2002
A49	2002-0086839	A1	Raz et al.	07-04-2002
A50	2002-0091097	A1	Bratzler et al.	07-11-2002
A51	2002-0102255	A1	Chang	08-01-2002
A52	2002-0156033	A1	Bratzler et al.	10-24-2002
A53	2002-0164341	A1	Davis et al.	11-07-2002
A54	2002-0165178	A1	Schetter et al	11-07-2002
A55	2002-0198165	A1	Bratzler et al.	12-26-2002
A56	2002-0164341	A1	Davis et al.	11-07-2002
A57	2003-0026782	A1	Krieg	02-02-2003
A58	2003-0026801	A1	Weiner et al.	02-06-2003
A59	2003-0027782	A1	Carson et al.	02-06-2003
A60	2003-0049266	A1	Fearon et al.	03-13-2003
A61	2003-0050261	A1	Krieg et al.	03-13-2003
A62	2003-0050263	A1	Krieg et al.	03-13-2003
A63	2003-0050268	A1	Krieg et al.	03-13-2003
A64	2003-0055014	A1	Bratzler	03-20-2003
A65	2003-0064064	A1	Dina et al.	04-03-2003
A66	2003-0078223	A1	Raz et al.	04-24-2003
A67	2003-0091599	A1	Davis et al.	05-15-2003
A68	2003-0092663	A1	Raz et al.	05-15-2003
A69	2003-0100527	A1	Krieg et al.	05-29-2003

EXAMINER:

/N. M. Minnifield/ (06/03/2008)

DATE CONSIDERED:

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.  
Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)			APPLICATION NO.: 10/817,165	ATTY. DOCKET NO.: C1039.70048US02
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: April 2, 2004	CONFIRMATION NO.: 1597
			APPLICANT: Krieg et al.	
Sheet	3	of	16	GROUP ART UNIT: 1645 EXAMINER: Nita M. Minnifield

A70	2003-0119773	A1	Raz et al.	06-26-2003
A71	2003-0139364	A1	Krieg et al.	07-24-2003
A72	2003-0148316	A1	Lipford et al.	08-07-2003
A73	2003-0148976	A1	Krieg et al.	08-07-2003
A74	2003-0166001	A1	Lipford	09-04-2003
A75	2003-0181406	A1	Schetter et al.	09-25-2003
A76	2003-0191079	A1	Krieg et al.	10-09-2003
A77	2003-0212026	A1	Krieg et al.	11-13-2003
A78	2003-0224010	A1	Davis et al.	12-04-2003
A79	2003-0232074	A1	Lipford et al.	12-18-2003
A80	2003-0232780	A1	Carson et al.	12-18-2003
A81	2003-0232856	A1	Macfarlane	12-18-2003
A82	2004-0006010	A1	Carson et al.	01-08-2004
A83	2004-0006034	A1	Raz et al.	01-08-2004
A84	2004-0009949	A1	Krieg	01-15-2004
A85	2004-0030118	A1	Wagner et al.	02-12-2004
A86	2004-0053880	A1	Krieg	03-18-2004
A87	2004-0067902	A9	Bratzler et al.	04-08-2004
A88	2004-0067905	A1	Krieg	04-08-2004
A89	2004-0087534	A1	Krieg et al.	05-06-2004
A90	2004-0087538	A1	Krieg et al.	05-06-2004
A91	2004-0092468	A1	Schwartz et al.	05-13-2004
A92	2004-0092472	A1	Krieg	05-13-2004
A93	2004-0106568	A1	Krieg et al.	06-03-2004
A94	2004-0131628	A1	Bratzler et al.	07-08-2004
A95	2004-0132685	A1	Krieg et al.	07-08-2004
A96	2004-0142469	A1	Krieg et al.	07-22-2004
A97	2004-0143112	A1	Krieg et al.	07-22-2004
A98	2004-0147468	A1	Krieg et al.	07-29-2004
A99	2004-0152649	A1	Krieg	08-05-2004
A100	2004-0152656	A1	Krieg et al.	08-05-2004
A101	2004-0152657	A1	Krieg et al.	08-05-2004
A102	2004-0162258	A1	Krieg et al.	08-19-2004
A103	2004-0162262	A1	Krieg et al.	08-19-2004
A104	2004-0167089	A1	Krieg et al.	08-26-2004
A105	2004-0171150	A1	Krieg et al.	09-02-2004
A106	2004-0171571	A1	Krieg et al.	09-02-2004

EXAMINER: /N. M. Minnifield/ (06/03/2008) DATE CONSIDERED:

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NMM/

FORM PTO-1449/A and B (modified PTO/SB/08)			APPLICATION NO.: 10/817,165	ATTY. DOCKET NO.: C1039.70048US02
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: April 2, 2004	CONFIRMATION NO.: 1597
			APPLICANT: Krieg et al.	
Sheet	4	of	16	GROUP ART UNIT: 1645 EXAMINER: Nita M. Minnifield

A107	2004-0181045	A1	Krieg et al.	09-16-2004
A108	2004-0198680	A1	Krieg	10-07-2004
A109	2004-0198688	A1	Krieg et al.	10-07-2004
A110	2004-0229835	A1	Krieg et al.	11-18-2004
A111	2004-0234512	A1	Wagner et al.	11-25-2004
A112	2004-0235770	A1	Davis et al.	11-25-2004
A113	2004-0235774	A1	Bratzler et al.	11-25-2004
A114	2004-0235777	A1	Wagner et al.	11-25-2004
A115	2004-0235778	A1	Wagner et al.	11-25-2004
A116	2004-0248837	A1	Raz et al.	12-09-2004
A117	2004-0266719	A1	McCluskie et al.	12-30-2004
A118	2005-0004061	A1	Krieg et al.	01-06-2005
A119	2005-0004062	A1	Krieg et al.	01-06-2005
A120	2005-0009774	A1	Krieg et al.	01-13-2005
A121	2005-0032734	A1	Davis et al.	02-10-2005
A122	2005-0032736	A1	Krieg et al.	02-10-2005
A123	2005-0037403	A1	Krieg et al.	02-17-2005
A124	2005-0037985	A1	Krieg et al.	02-17-2005
A125	2005-0043529	A1	Davis et al.	02-24-2005
A126	2005-0049215	A1	Krieg et al.	03-03-2005
A127	2005-0049216	A1	Krieg et al.	03-03-2005
A128	2005-0054601	A1	Wagner et al.	03-10-2005
A129	2005-0054602	A1	Krieg et al.	03-10-2005
A130	2005-0059619	A1	Krieg et al.	03-17-2005
A131	2005-0059625	A1	Krieg et al.	03-17-2005
A132	2005-0070491	A1	Krieg et al.	03-31-2005
A133	2005-0075302	A1	Hutcherson et al.	04-07-2005
A134	2005-0100983	A1	Bauer et al.	05-12-2005
A135	2005-0101554	A1	Krieg et al.	05-12-2005
A136	2005-0101557	A1	Krieg et al.	05-12-2005
A137	2005-0119273	A1	Lipford et al.	06-02-2005
A138	2005-0123523	A1	Krieg et al.	06-09-2005
A139	2005-0130911	A1	Uhlmann et al.	06-16-2005
A140	2005-0148537	A1	Krieg et al.	07-07-2005
A141	2005-0169888	A1	Hartman et al.	08-04-2005
A142	2005-0171047	A1	Krieg et al.	08-04-2005
A143	2005-0181422	A1	Bauer et al.	08-18-2005

EXAMINER: /N. M. Minnifield/ (06/03/2008) DATE CONSIDERED:

<sup>a</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NMM/

FORM PTO-1449/A and B (modified PTO/SB/08)

APPLICATION NO.: 10/817,165

ATTY. DOCKET NO.: C1039.70048US02

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

FILING DATE: April 2, 2004

CONFIRMATION NO.: 1597

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

Sheet 5 of 16

	A144	2005-0182017	A1	Krieg	08-18-2005
	A145	2005-0197314	A1	Krieg et al.	09-08-2005
	A146	2005-0215500	A1	Krieg et al.	09-29-2005
	A147	2005-0215501	A1	Lipford et al.	09-29-2005
	A148	2005-0233995	A1	Krieg et al.	10-20-2005
	A149	2005-0233999	A1	Krieg et al.	10-20-2005
	A150	2005-0239732	A1	Krieg et al.	10-27-2005
	A151	2005-0239733	A1	Jurk et al.	10-27-2005
	A152	2005-0239734	A1	Uhlmann et al.	10-27-2005
	A153	2005-0239736	A1	Krieg et al.	10-27-2005
	A154	2005-0244379	A1	Krieg et al.	11-03-2005
	A155	2005-0244380	A1	Krieg et al.	11-03-2005
	A156	2005-0245477	A1	Krieg et al.	11-03-2005
	A157	2005-0250726	A1	Krieg et al.	11-10-2005
	A158	2005-0256073	A1	Lipford et al.	11-17-2005
	A159	2005-0267064	A1	Krieg et al.	12-01-2005
	A160	2005-0277604	A1	Krieg et al.	12-15-2005
	A161	2005-0277609	A1	Krieg et al.	12-15-2005
	A162	2006-0003955	A1	Krieg et al.	01-05-2006
	A163	2006-0003962	A1	Ahluwalia et al.	01-05-2006
	A164	2006-0019916	A1	Krieg et al.	01-26-2006
	A165	2006-0019923	A1	Davis et al.	01-26-2006
	A166	2006-0058251	A1	Krieg et al.	03-16-2006
	A167	2006-0089326	A1	Krieg et al.	04-27-2006
	A168	2006-0094683	A1	Krieg et al.	05-04-2006
	A169	2006-0140875	A1	Krieg et al.	06-29-2006
	A170	2006-0154890	A1	Bratzler et al.	07-13-2006
	A171	2006-0172966	A1	Lipford et al.	08-03-2006
	A172	2006-0188913	A1	Krieg et al.	08-24-2006
	A173	2006-0211639	A1	Bratzler et al.	09-21-2006
	A174	2006-0211644	A1	Krieg et al.	09-21-2006
	A175	2006-0229271	A1	Krieg et al.	10-12-2006
	A176	2006-0241076	A1	Uhlmann et al.	10-26-2006
	A177	2006-0246035	A1	Ahluwalia et al.	11-02-2006
	A178	2006-0286070	A1	Hartmann et al.	12-21-2006
	A179	2006-0287263	A1	Davis et al.	12-21-2006
	A180	2007-0009482	A1	Krieg et al.	01-11-2007

EXAMINER:

/N. M. Minnifield/ (06/03/2008)

DATE CONSIDERED:

<sup>a</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

FILING DATE: April 2, 2004

CONFIRMATION NO.: 1597

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

Sheet 6 of 16

A181	2007-0010470	A1	Krieg et al.	01-11-2007
A182	2007-0037767	A1	Bratzler et al.	02-15-2007
A183	2007-0065467	A1	Krieg et al.	03-22-2007
A184	2007-0066553	A1	Krieg et al.	03-22-2007
A185	2007-0066554	A1	Krieg et al.	03-22-2007
A186	2007-0078104	A1	Krieg et al.	04-05-2007
A187	2007-0129320	A9	Davis et al.	06-07-2007
A188	2007-0142315	A1	Forsbach et al.	06-21-2007
A189	2007-0184465	A1	Wagner et al.	08-09-2007
A190	2007-0202128	A1	Krieg et al.	08-30-2007

## FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
*	B1	EP	0 468 520	A2	Mitsui Toatsu Chemicals, Inc.	01-29-1992	
	B2	WO	96/32138	A1	Milkhaus Laboratory	10-17-1996	
	B3	WO	96/40162	A1	East Carolina University	12-19-1996	
	B4	WO	98/55495	A2	Dynavax Technologies Corporation	12-10-1998	
	B5	WO	99/11275	A2	The Regents of the University of California	03-11-1999	
*	B6	WO	99/56755	A1	University of Iowa Research Foundation	11-11-1999	
*	B7	WO	00/06588	A1	University of Iowa Research Foundation	02-10-2000	
*	B8	WO	00/14217	A2	CPG Immunopharmaceuticals GMBH	03-16-2000	
*	B9	WO	00/54803	A2	Panacea Pharmaceuticals, LLC.	09-21-2000	
*	B10	WO	00/67023	A1	CPG Immunopharmaceuticals GMBH	11-09-2000	
	B11	WO	01/45750	A1	Regents of the University of California	06-28-2001	
*	B12	WO	2004/007743	A2	Coley Pharmaceutical GMBH	01-22-2004	
	B13	WO	2004/026888	A2	Coley Pharmaceutical GMBH	04-01-2004	
	B14	WO	2004/094671	A2	Coley Pharmaceutical GMBH	11-04-2004	
	B15	WO	2006/080946	A2	Coley Pharmaceutical GMBH	08-03-2006	
	B16	WO	2007/031877	A2	Coley Pharmaceutical GMBH	03-22-2007	
	B17	WO	2007/038720	A2	Coley Pharmaceutical GMBH	04-05-2007	

EXAMINER:

/N. M. Minnifield/ (06/03/2008)

DATE CONSIDERED:

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Sheet 7 of 16

## OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1	[No Author Listed] National Institute of Health, Publication Number 97-4051, July 1997.	
	C2	Press Release, January 2007, "Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy".	
	C3	Press Release, June 2007, "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer".	
	C4	ANITESCU et al., Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. <i>J Interferon Cytokine Res.</i> 1997 Dec;17(12):781-8.	
*	C5	BALLAS et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. <i>J Immunol.</i> 1996 Sep 1;157(5):1840-5.	
*	C6	BOGGS et al., Characterization and modulation of immune stimulation by modified oligonucleotides. <i>Antisense Nucleic Acid Drug Dev.</i> 1997 Oct;7(5):461-71.	
	C7	BROIDE et al., DNA-Based immunization for asthma. <i>Int Arch Allergy Immunol.</i> 1999 Feb-Apr;118(2-4):453-6.	
	C8	BROIDE et al., Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. <i>J Immunol.</i> 1998 Dec 15;161(12):7054-62.	
	C9	BROIDE et al., Modulation of asthmatic response by immunostimulatory DNA sequences. <i>Springer Semin Immunopathol.</i> 2000;22(1-2):117-24.	
*	C10	CARSON et al., Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination. <i>J Exp Med.</i> 1997 Nov 17;186(10):1621-2.	
	C11	CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. <i>Clin Immunol Immunopathol.</i> 1997 Aug;84(2):185-93.	
*	C12	CHU et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. <i>J Exp Med.</i> 1997 Nov 17;186(10):1623-31.	
	C13	COOPER et al., CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. <i>J Clin Immunol.</i> 2004 Nov;24(6):693-701.	
	C14	COOPER et al., Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. <i>Vaccine.</i> 2004 Aug 13;22(23-24):3136-43.	
*	C15	COWDERY et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. <i>J Immunol.</i> 1996 Jun 15;156(12):4570-5.	
	C16	CRETICOS et al., Immunotherapy with immunostimulatory oligonucleotides linked to purified ragweed Amb a 1 allergen: effects on antibody production, nasal allergen provocation, and ragweed seasonal rhinitis. <i>J Allergy Clin Immunol.</i> 2002;109(4):741-3.	
*	C17	DURHAM et al., Immunotherapy and allergic inflammation. <i>Clin Exp Allergy.</i> 1991 Jan;21 Suppl 1:206-10.	
	C18	FORNADLEY, Allergy immunotherapy. <i>Otolaryngol Clin North Am.</i> 1998 Feb;31(1):111-27. Abstract Only.	
	C19	HALPERIN et al., A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. <i>Vaccine.</i> 2003 Jun 2;21(19-20):2461-7.	

EXAMINER:

/N. M. Minnifield/ (06/03/2008)

DATE CONSIDERED:

<sup>a</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)

APPLICATION NO.: 10/817,165

ATTY. DOCKET NO.: C1039.70048US02

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

FILING DATE: April 2, 2004

CONFIRMATION NO.: 1597

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

Sheet 8 of 16

*	C20	HALPERN et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. <i>Cell Immunol.</i> 1996 Jan 10;167(1):72-8.	
	C21	HOGG, The pathology of asthma. <i>APMIS.</i> 1997 Oct;105(10):735-45.	
	C22	HORNER et al., Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. <i>J Allergy Clin Immunol.</i> 2002 Nov;110(5):706-12.	
	C23	HUSSAIN et al., CpG oligodeoxynucleotides: a novel therapeutic approach for atopic disorders. <i>Curr Drug Targets Inflamm Allergy.</i> 2003 Sep;2(3):199-205.	
	C24	JAIN et al., CpG DNA and immunotherapy of allergic airway diseases. <i>Clin Exp Allergy.</i> 2003 Oct;33(10):1330-5.	
	C25	JAKOB et al., Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. <i>J Immunol.</i> 1998 Sep 15;161(6):3042-9.	
*	C26	KATAOKA et al., Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG. <i>Jpn J Cancer Res.</i> 1992 Mar;83(3):244-7.	
	C27	KATAOKA et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from <i>Mycobacterium bovis</i> BCG complexed with poly-L-lysine and carboxymethylcellulose. <i>Jpn J Med Sci Biol.</i> 1990 Oct;43(5):171-82.	
	C28	KAY et al., Allergy and allergic diseases. Second of two parts. <i>N Engl J Med.</i> 2001 Jan 11;344(2):109-13.	
*	C29	KIMURA et al., Binding of oligoguanosinate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN. <i>J Biochem (Tokyo).</i> 1994 Nov;116(5):991-4.	
	C30	KITAGAKI et al., Oral administration of CpG-ODNs suppresses antigen-induced asthma in mice. <i>Clin Exp Immunol.</i> 2006 Feb;143(2):249-59.	
*	C31	KLINE et al., The American Federation for Clinical Research, Midwestern section and Eastern section annual meetings. 1996. Abstracts. <i>J Investig Med.</i> 1996 Sep;44(7): 380A.	
*	C32	KLINE et al., Biomedicine '97. Medical research from bench to bedside. Washington, D.C., April 25-27, 1997. Abstracts. <i>J Investig Med.</i> 1997 Mar;45(3): 282A.	
*	C33	KLINE et al., American Federation for Medical Research Midwestern Regional Meeting. Chicago, Illinois, September 25-27, 1997. Abstracts. <i>J Investig Med.</i> 1997 Sep;45(7): 298A.	
	C34	KLINE et al., CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. <i>J Allergy Clin Immunol.</i> 1999 Dec;104(6):1258-64.	
	C35	KLINE et al., Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. <i>Am J Physiol Lung Cell Mol Physiol.</i> 2002 Jul;283(1):L170-9.	
	C36	KLINE et al., Effects of CpG DNA on Th1/Th2 balance in asthma. <i>Curr Top Microbiol Immunol.</i> 2000;247:211-25.	
	C37	KLINMAN et al., Contribution of CpG motifs to the immunogenicity of DNA vaccines. <i>J Immunol.</i> 1997 Apr 15;158(8):3635-9.	
*	C38	KLINMAN et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. <i>Proc Natl Acad Sci U S A.</i> 1996 Apr 29;93(7):2879-83.	

EXAMINER:

/N. M. Minnifield/ (06/03/2008)

DATE CONSIDERED:

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
Sheet	9	of	16

APPLICATION NO.: 10/817,165	ATTY. DOCKET NO.: C1039.70048US02
FILING DATE: April 2, 2004	CONFIRMATION NO.: 1597
APPLICANT: Krieg et al.	
GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

	C39	KOU et al., [Analysis and regulation of interferon-gamma production by peripheral blood lymphocytes from patients with bronchial asthma] Arerugi. 1994 Mar;43(3):482-91. Japanese. Abstract Only.	
	C40	KRIEG et al., Immune effects and therapeutic applications of CpG motifs in bacterial DNA. Immunopharmacology. 2000 Jul 25;48(3):303-5.	
	C41	KRIEG et al., Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel un-methylated CpG motifs. American College of Rheumatology 58 <sup>th</sup> National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl).	
*	C42	KRIEG et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. 1996 Summer;6(2):133-9.	
*	C43	KRIEG et al., Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res Dev. 1995 Winter;5(4):241.	
*	C44	KRIEG et al., Leukocyte stimulation by oligodeoxynucleotides. In: Applied Antisense Oligonucleotide Technology. 1998;431-48.	
*	C45	KRIEG, CpG DNA: a pathogenic factor in systemic lupus erythematosus? J Clin Immunol. 1995 Nov;15(6):284-92.	
*	C46	KRIEG et al., CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995 Apr 6;374(6522):546-9.	
*	C47	KRIEG et al., The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 1998 Jan;6(1):23-7.	
	C48	KRIEG, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med. 1996 Aug;128(2):128-33.	
	C49	KRIEG et al., Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal L. monocytogenes challenge. 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996;116.	
	C50	KRIEG et al., The CpG motif: Implications for clinical immunology. BioDrugs. 1998 Nov 1;10(5):341-6.	
	C51	KRIEG et al., Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12631-6.	
	C52	KRIEG et al., CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol. 1998 Sep 1;161(5):2428-34.	
	C53	KRIEG et al., Infection. In: McGraw Hill Book. 1996;242-3.	
	C54	KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.	
	C55	KRIEG et al., Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004 Nov-Dec;27(6):460-71.	
	C56	KRIEG, Immune effects and mechanisms of action of CpG motifs. Vaccine. 2000 Nov 8;19(6):618-22.	
	C57	KURAMOTO et al., Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. Int J Immunopharmacol. 1992 Jul;14(5):773-82.	
*	C58	KURAMOTO et al., Oligonucleotide sequences required for natural killer cell activation. Jpn J Cancer Res. 1992 Nov;83(11):1128-31.	

EXAMINER: /N. M. Minnifield/ (06/03/2008)	DATE CONSIDERED:
--	------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Sheet 10 of 16

	C59	KURAMOTO et al., In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG. <i>Microbiol Immunol.</i> 1989;33(11):929-40.	
	C60	LECLERC et al., The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. <i>Cell Immunol.</i> 1997 Aug 1;179(2):97-106.	
*	C61	LEIBSON et al., Role of gamma-interferon in antibody-producing responses. <i>Nature.</i> 1984 Jun 28-Jul 4;309(5971):799-801.	
*	C62	LIPFORD et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. <i>Eur J Immunol.</i> 1997 Sep;27(9):2340-4.	
*	C63	LIPFORD et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. <i>Eur J Immunol.</i> 1997 Dec;27(12):3420-6.	
	C64	LIU et al., CpG ODN is an effective adjuvant in immunization with tumor antigen. <i>J Invest Med.</i> 1997 Sept 7;45(7):33A.	
	C65	LUKACS et al., Interleukin-4-dependent pulmonary eosinophil infiltration in a murine model of asthma. <i>Am J Respir Cell Mol Biol.</i> 1994 May;10(5):526-32.	
	C66	LUKACS et al., C-C chemokine-induced eosinophil chemotaxis during allergic airway inflammation. <i>J Leukoc Biol.</i> 1996 Nov;60(5):573-8.	
	C67	MARSHALL et al., Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCS from human patients with ragweed allergy. <i>J Allergy Clin Immunol.</i> 2001 Aug;108(2):191-7.	
	C68	McCLUSKIE et al., CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. <i>J Immunol.</i> 1998 Nov 1;161(9):4463-6.	
*	C69	MESSINA et al., The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens. <i>Cell Immunol.</i> 1993 Mar;147(1):148-57.	
	C70	MOSMANN et al., The expanding universe of T-cell subsets: Th1, Th2 and more. <i>Immunol Today.</i> 1996 Mar;17(3):138-46.	
*	C71	NYCE et al., DNA antisense therapy for asthma in an animal model. <i>Nature.</i> 1997 Feb 20;385(6618):721-5.	
*	C72	PISETSKY et al., The immunologic properties of DNA. <i>J Immunol.</i> 1996 Jan 15;156(2):421-3.	
*	C73	PISETSKY, Immunologic consequences of nucleic acid therapy. <i>Antisense Res Dev.</i> 1995 Fall;5(3):219-25.	
*	C74	PISETSKY et al., Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. <i>Mol Biol Rep.</i> 1993 Oct;18(3):217-21.	
	C75	PISETSKY, The influence of base sequence on the immunostimulatory properties of DNA. <i>Immunol Res.</i> 1999;19(1):35-46.	
*	C76	PISETSKY et al., Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. <i>Life Sci.</i> 1994;54(2):101-7.	
	C77	RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. ACR Poster Session C: Cytokines and Inflammatory Mediators. 1996 Oct 20; Abstract 615.	
*	C78	RAZ et al., Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. <i>Proc Natl Acad Sci U S A.</i> 1996 May 14;93(10):5141-5.	

EXAMINER:

/N. M. Minnifield/ (06/03/2008)

DATE CONSIDERED:

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/817,165	ATTY. DOCKET NO.: C1039.70048US02
				FILING DATE: April 2, 2004	CONFIRMATION NO.: 1597
				APPLICANT: Krieg et al.	
Sheet	11	of	16	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

C79	RICCI et al., T cells, cytokines, IgE and allergic airways inflammation. <i>J Investig Allergol Clin Immunol.</i> 1994 Sep-Oct;4(5):214-20.	
C80	ROBINSON et al., Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. <i>N Engl J Med.</i> 1992 Jan 30;326(5):298-304.	
*	C81 ROMAN et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. <i>Nat Med.</i> 1997 Aug;3(8):849-54.	
	C82 ROMAN et al., Gene immunization for allergic disorders. <i>Springer Semin Immunopathol.</i> 1997;19(2):223-32.	
*	C83 SATO et al., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. <i>Science.</i> 1996 Jul 19;273(5273):352-4.	
*	C84 SCHWARTZ et al., CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. <i>J Clin Invest.</i> 1997 Jul 1;100(1):68-73.	
	C85 SEREBRISKY et al., CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. <i>J Immunol.</i> 2000 Nov 15;165(10):5906-12.	
	C86 SIEGRIST et al., Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. <i>Vaccine.</i> 2004 Dec 16;23(5):615-22.	
	C87 SIMONS et al., Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. <i>J Allergy Clin Immunol.</i> 2004 Jun;113(6):1144-51.	
	C88 SJÖLANDER et al., Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. <i>Cell Immunol.</i> 1997 Apr 10;177(1):69-76.	
	C89 SPARWASSER et al., Bacterial DNA causes septic shock. <i>Nature.</i> 1997 Mar 27;386(6623):336-7.	
*	C90 SPARWASSER et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. <i>Eur J Immunol.</i> 1997 Jul;27(7):1671-9.	
	C91 SPEISER et al., Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. <i>J Clin Invest.</i> 2005 Mar;115(3):739-46.	
	C92 SPIEGELBERG et al., DNA-based approaches to the treatment of allergies. <i>Curr Opin Mol Ther.</i> 2002 Feb;4(1):64-71.	
	C93 STEIN et al., Problems in interpretation of data derived from <i>in vitro</i> and <i>in vivo</i> use of antisense oligodeoxynucleotides. <i>Antisense Res Dev.</i> 1994 Summer;4(2):67-9.	
	C94 STEIN et al., Non-antisense effects of oligodeoxynucleotides. <i>Antisense Technology.</i> 1997; ch11: 241-64.	
*	C95 TOKUNAGA et al., A synthetic single-stranded DNA, poly(dG,dC), induces interferon-alpha/beta and -gamma, augments natural killer activity, and suppresses tumor growth. <i>Jpn J Cancer Res.</i> 1988 Jun;79(6):682-6.	
*	C96 TOKUNAGA et al., Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG induce interferons and activate natural killer cells. <i>Microbiol Immunol.</i> 1992;36(1):55-66.	
	C97 VAN OJIK et al., Phase I/II study with CpG 7909 as adjuvant to vaccination with MAGE-3 protein in patients with MAGE-3 positive tumors. <i>Ann Oncol.</i> 2003;13:157. Abstract 5790.	
	C98 VAN UDEN et al., Immunostimulatory DNA and applications to allergic disease. <i>J Allergy Clin Immunol.</i> 1999 Nov;104(5):902-10.	
	C99 WEERATNA et al., Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. <i>Antisense Nucleic Acid Drug Dev.</i> 1998 Aug;8(4):351-6.	

EXAMINER:

/N. M. Minnifield/ (06/03/2008)

DATE CONSIDERED:

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Sheet 12 of 16

	C100	WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10833-7.	
	C101	WEISS et al., Design of protective and therapeutic DNA vaccines for the treatment of allergic diseases. Curr Drug Targets Inflamm Allergy. 2005 Oct;4(5):585-97.	
*	C102	YAMAMOTO et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTC to murine splenocytes enhances interferon production and natural killer activity. Microbiol Immunol. 1994;38(10):831-6.	
*	C103	YAMAMOTO et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J Immunol. 1992 Jun 15;148(12):4072-6.	
*	C104	YAMAMOTO et al., [Commemorative lecture of receiving Imamura Memorial Prize. II. Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BCG] Kekkaku. 1994 Sep;69(9):571-4. Japanese.	
*	C105	YAMAMOTO et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length. Antisense Res Dev. 1994 Summer;4(2):119-22.	
*	C106	YAMAMOTO et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro. Jpn J Cancer Res. 1994 Aug;85(8):775-9.	
	C107	YAMAMOTO, Cytokine production inducing action of oligo DNA. Rinsho Meneki. 1997; 29(9): 1178-84. Japanese.	Yes
	C108	YI et al. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol. 1998 Nov 1;161(9):4493-7.	
*	C109	YI et al., Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol. 1996 Dec 15;157(12):5394-402.	
*	C110	YI et al., IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol. 1996 Jan 15;156(2):558-64.	
	C111	YI et al. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol. 1998 Jun 15;160(12):5898-906.	
	C112	ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):495-502.	
*	C113	Patent Interference No. 105,171. Iowa Preliminary Motion 3 (for judgment based on failure to comply with 35 U.S.C. 135(b)). (Electronically filed, unsigned). June 7, 2004.	
*	C114	Patent Interference No. 105,171. Iowa Preliminary Motion 4 (for judgment of no interference in fact). (Electronically filed, unsigned). June 7, 2004.	
*	C115	Patent Interference No. 105,171. Iowa Preliminary Motion 5 (for judgment based on lack of enablement). (Electronically filed, unsigned). June 7, 2004.	
*	C116	Patent Interference No. 105,171. Iowa Preliminary Motion 6 (for judgment based on lack of adequate written description). (Electronically filed, unsigned). June 7, 2004.	
*	C117	Patent Interference No. 105,171. Iowa Preliminary Motion 7 (motion to redefine interference to designate claims as not corresponding to the Count). (Electronically filed, unsigned). June 7, 2004.	

## EXAMINER:

/N. M. Minnifield/ (06/03/2008)

## DATE CONSIDERED:

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/817,165	ATTY. DOCKET NO.: C1039.70048US02
				FILING DATE: April 2, 2004	CONFIRMATION NO.: 1597
				APPLICANT: Krieg et al.	
Sheet	13	of	16	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

*	C118	Patent Interference No. 105,171. Iowa Preliminary Motion 8 (contingent motion to redefine the Count). (Electronically filed, unsigned). June 7, 2004.	
*	C119	Patent Interference No. 105,171. Iowa Preliminary Motion 9 (motion for benefit of earlier application). (Electronically filed, unsigned). June 7, 2004.	
*	C120	Patent Interference No. 105,171. Iowa Preliminary Motion 10 (contingent motion to redefine the interference by adding a continuation application). (Electronically filed, unsigned). July 2, 2004.	
*	C121	Patent Interference No. 105,171. Regents of the University of California Opposition 3 (to Iowa Preliminary Motion 3 for judgment under 35 USC 135(b)). September 9, 2004.	
*	C122	Patent Interference No. 105,171. Regents of the University of California Opposition 4 (to Iowa Preliminary Motion 4 for judgment of no interference in fact). September 9, 2004.	
*	C123	Patent Interference No. 105,171. Regents of the University of California Opposition 5 (to Iowa Preliminary Motion 5 for judgment that UC's claim is not enabled). September 9, 2004.	
*	C124	Patent Interference No. 105,171. Regents of the University of California Opposition 6 (to Iowa Preliminary Motion 6 for judgment based on lack of adequate written description). September 9, 2004.	
*	C125	Patent Interference No. 105,171. Regents of the University of California Opposition 7 (to Iowa Preliminary Motion 7 to redefine the interference). September 9, 2004.	
*	C126	Patent Interference No. 105,171. Regents of the University of California Opposition 8 (to Iowa Preliminary Motion 8 to redefine the Count). September 9, 2004.	
*	C127	Patent Interference No. 105,171. Regents of the University of California Response 9 (to Iowa Contingent Motion 9 for benefit). September 9, 2004.	
*	C128	Patent Interference No. 105,171. Regents of the University of California Opposition 10 (to Iowa Contingent Motion 10 to redefine the interference). September 9, 2004.	
*	C129	Patent Interference No. 105,171. Regents of the University of California Opposition 11 (to Iowa Contingent Motion 11 to suppress). October 15, 2004.	
*	C130	Patent Interference No. 105,171. Iowa Reply 3 (in support of Iowa Preliminary Motion 3 for judgment under 35 U.S.C. §135(b)) (Electronically filed, unsigned). October 15, 2004.	
*	C131	Patent Interference No. 105,171. Iowa Reply 4 (in support of Iowa Preliminary Motion for judgment of no interference in fact) (Electronically filed, unsigned). October 15, 2004.	
*	C132	Patent Interference No. 105,171. Iowa Reply 5 (in support of Iowa Preliminary Motion 5 for judgment that UC's claim 205 is not enabled) (Electronically filed, unsigned). October 15, 2004.	
*	C133	Patent Interference No. 105,171. Iowa Reply 6 (in support of Iowa Preliminary Motion 6 for judgment based on lack of adequate written description) (Electronically filed, unsigned). October 15, 2004.	
*	C134	Patent Interference No. 105,171. Iowa Reply 7 (in support of Iowa Preliminary Motion 7 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
*	C135	Patent Interference No. 105,171. Iowa Reply 8 (in support of Iowa Preliminary Motion 8 to redefine the count) (Electronically filed, unsigned). October 15, 2004.	
*	C136	Patent Interference No. 105,171. Iowa Reply 10 (in support of Iowa Preliminary Motion 10 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
*	C137	Patent Interference No. 105,171. Iowa Reply 11 (in support of Iowa Miscellaneous Motion to suppress). (Electronically filed, unsigned). October 18, 2004.	
*	C138	Patent Interference No. 105,171. Regents of the University of California Preliminary Statement. June 7, 2004.	

EXAMINER:	DATE CONSIDERED:
/N. M. Minnifield/ (06/03/2008)	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)			APPLICATION NO.: 10/817,165	ATTY. DOCKET NO.: C1039.70048US02
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			FILING DATE: April 2, 2004	CONFIRMATION NO.: 1597
			APPLICANT: Krieg et al.	
Sheet	14	of	16	GROUP ART UNIT: 1645 EXAMINER: Nita M. Minnfield

*	C139	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 1 (to designate additional claims of Iowa patent as corresponding to the Count). June 7, 2004.	
*	C140	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 2 (for judgment based on lack of written description support and introducing new matter). June 7, 2004.	
*	C141	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 3 (for judgment based on anticipation). June 7, 2004.	
*	C142	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 4 (for judgment based on obviousness). June 7, 2004.	
*	C143	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 5 (for judgment based on anticipation). June 7, 2004.	
*	C144	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 6 (for judgment based on inequitable conduct). June 7, 2004.	
*	C145	Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 7 (for benefit of an earlier application under 37 CFR 1.633(j)). July 2, 2004.	
*	C146	Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 8 (to add additional claims under 37 CFR 1.633(c)(2) and (i)). July 2, 2004.	
*	C147	Amended Claims for Application Number 09/265,191, filed March 10, 1999.	
*	C148	Patent Interference No. 105,171. Iowa Opposition 1 (opposition to motion to designate additional claims as corresponding to the Count) (Electronically filed, unsigned). September 9, 2004.	
*	C149	Patent Interference No. 105,171. Iowa Opposition 2 (opposition to motion for judgment based on lack of written description support and introducing new matter) (Electronically filed, unsigned). September 9, 2004.	
*	C150	Patent Interference No. 105,171. Iowa Opposition 3 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
*	C151	Patent Interference No. 105,171. Iowa Opposition 4 (opposition to motion for judgment based on obviousness) (Electronically filed, unsigned). September 9, 2004.	
*	C152	Patent Interference No. 105,171. Iowa Opposition 5 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
*	C153	Patent Interference No. 105,171. Iowa Opposition 6 (opposition to motion for judgment based on inequitable conduct) (Electronically filed, unsigned). September 9, 2004.	
*	C154	Patent Interference No. 105,171. Iowa Opposition 7 (opposition to motion for benefit of an earlier application under 7 CFR 1.633(j)) (Electronically filed, unsigned). September 9, 2004.	
*	C155	Patent Interference No. 105,171. Iowa Opposition 8 (opposition to motion to add additional claims under 37 CFR 1.633 (2) and (i)) (Electronically filed, unsigned). September 9, 2004.	
*	C156	Patent Interference No. 105,171. Regents of the University of California Reply 1 (to Iowa's opposition to UC's motion to designate Iowa claims as corresponding to the Count). October 15, 2004.	
*	C157	Patent Interference No. 105,171. Regents of the University of California Reply 2 (to Iowa's opposition to UC Preliminary Motion 2 for Judgment). October 15, 2004.	
*	C158	Patent Interference No. 105,171. Regents of the University of California Reply 3 (to Iowa's Opposition to UC Preliminary Motion 3 for Judgment). October 15, 2004.	
*	C159	Patent Interference No. 105,171. Regents of the University of California Reply 4 (to Iowa's Opposition to UC Preliminary Motion 4 for Judgment). October 15, 2004.	

EXAMINER: /N. M. Minnfield/ (06/03/2008)	DATE CONSIDERED:
---	------------------

<sup>a</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/817,165	ATTY. DOCKET NO.: C1039.70048US02
				FILING DATE: April 2, 2004	CONFIRMATION NO.: 1597
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield
Sheet	15	of	16		

*	C160	Patent Interference No. 105,171. Regents of the University of California Reply 5 (to Iowa's Opposition to UC Preliminary Motion 5 for Judgment). October 15, 2004.	
*	C161	Patent Interference No. 105,171. Regents of the University of California Reply 6 (to Iowa's opposition to UC Preliminary Motion 6 for judgment). October 15, 2004.	
*	C162	Patent Interference No. 105,171. Regents of the University of California Reply 7 (to Iowa's Opposition to UC Preliminary Motion 7 for Benefit). October 15, 2004.	
*	C163	Patent Interference No. 105,171. Regents of the University of California Reply 8 (to Iowa's Opposition to UC Preliminary Motion 8 to add additional claims). October 15, 2004.	
*	C164	Patent Interference No. 105,171. Decision on Motion under 37 CFR §41.125. March 10, 2005.	
*	C165	Patent Interference No. 105,171. Judgment and Order. March 10, 2005.	
*	C166	Patent Interference No. 105,171. Regents of the University of California. Brief of Appellant. July 5, 2005.	
*	C167	Patent Interference No. 105,171. University of Iowa and Coley Pharmaceutical Group, Inc. Brief of Appellees. August 17, 2005.	
*	C168	Patent Interference No. 105,171. Regents of the University of California. Reply Brief of Appellant. September 6, 2005.	
*	C169	Patent Interference No. 105,171. Regents of the University of California. Decision of CAFC. July 17, 2006.	
	C170	Patent Interference No. 105,526. Krieg Substantive Motion 1 (for unpatentability based on interference estoppel). (Electronically filed, unsigned).	
	C171	Patent Interference No. 105,526.. Krieg Substantive Motion 2 (for judgment based on inadequate written description and/or enablement). (Electronically filed, unsigned). June 18, 2007.	
	C172	Patent Interference No. 105,526. Krieg Contingent Responsive Motion (to add new claims 104 and 105). (Electronically filed, unsigned). July 25, 2007.	
	C173	Patent Interference No. 105,526. Krieg Substantive Motion 3 (for judgment based on prior art). (Electronically filed, unsigned). June 18, 2007.	
	C174	Patent Interference No. 105,526. Raz Motion 1 (Unpatentability of Krieg Claims under 35 U.S.C. § 112, First Paragraph). (Electronically filed, unsigned). June 18, 2007.	
	C175	Patent Interference No. 105,526. Raz Motion 2 (Raising a Threshold Issue of No Interference-in-Fact). (Electronically filed, unsigned). June 18, 2007.	
	C176	Patent Interference No. 105,526.. Raz Motion 3 (Krieg's Claims are Unpatentable Over Prior Art Under 35 U.S.C. § 102(b)) (Electronically filed, unsigned). June 18, 2007.	
	C177	Patent Interference No. 105,526. Raz Motion 4 (To Designate Krieg Claims 46 and 82-84 as Corresponding to Count 1). (Electronically filed, unsigned). June 18, 2007.	
	C178	Patent Interference No. 105,526. Raz Responsive Miscellaneous Motion 5 (To revive the Raz Parent Application) (Electronically filed, unsigned) July 25, 2007.	
	C179	Patent Interference No. 105,526. Raz Contingent Responsive Motion 6 (To Add a New Claim 58) (Electronically filed, unsigned) July 25, 2007.	
	C180	Patent Interference No. 105,526. Krieg Opposition 1 (Opposition to Motion for Lack of Enablement and Written Description) (Electronically filed, unsigned) September 10, 2007.	
	C181	Patent Interference No. 105,526. Krieg Opposition 2 (to Raz Motion 2) (Electronically filed, unsigned) September 10, 2007.	
	C182	Patent Interference No. 105,526. Krieg Opposition 3 (To Raz Motion 3) (Electronically filed, unsigned) September 10, 2007.	

EXAMINER:

/N. M. Minnifield/ (06/03/2008)

DATE CONSIDERED:

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NMM/

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/817,165	ATTY. DOCKET NO.: C1039.70048US02
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: April 2, 2004	CONFIRMATION NO.: 1597
				APPLICANT: Krieg et al.	
Sheet	16	of	16	GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield

C183	Patent Interference No. 105,526. Krieg Opposition 4 (Opposition to Motion for Designating Claims 46 and 82-84 as Corresponding to the Court) (Electronically filed, unsigned) September 10, 2007.	
C184	Patent Interference No. 105,526. Raz Opposition 1 (Opposing Krieg Substantive Motion 1) (Electronically filed, unsigned) September 10, 2007.	
C185	Patent Interference No. 105,526. Raz Opposition 2 (Opposing Krieg Substantive Motion 2) (Electronically filed, unsigned) September 10, 2007.	
C186	Patent Interference No. 105,526. Raz Opposition 4 (Opposing Krieg Contingent Responsive Motion to Add New Claims 104 and 105) (Electronically filed, unsigned) September 10, 2007.	
C187	Patent Interference No. 105,526. Krieg Reply 1 (Reply to Raz opposition 1) October 5, 2007	
C188	Patent Interference No. 105,526. Krieg Reply 2 (Reply to Raz opposition 2) October 5, 2007	
C189	Patent Interference No. 105,526. Krieg Reply 4 (Reply to Raz opposition 4) October 5, 2007	
C190	Patent Interference No. 105,526. Raz Reply 1 (Reply to Krieg opposition 1) October 5, 2007	
C191	Patent Interference No. 105,526. Raz Reply 2 (Reply to Krieg opposition 2) October 5, 2007	
C192	Patent Interference No. 105,526. Raz Reply 3 (Reply to Krieg opposition 3) October 5, 2007	
C193	Patent Interference No. 105,526. Raz Reply 4 (Reply to Krieg opposition 4) October 5, 2007	
C194	Patent Interference No. 105,526. Raz Reply 6 (Reply to Krieg opposition 6) October 5, 2007	

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818, 918, filed March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER: /N. M. Minnifield/ (06/03/2008)	DATE CONSIDERED:
--	------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NMM/